Junki Tomita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junki Tomita has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Shoko Itakura
Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan
2 shared publications - Yutaka Inoue
Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, Sakado, Japan
2 shared publications - Akie Okada
Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado 350-0295, Saitama, Japan
1 shared publication - Harue Nomura
Department of Microbiology, School of Pharmaceutical Sciences, Josai University
1 shared publication - Hiroaki Todo
Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
1 shared publication - Keito Suzuki
Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan
1 shared publication
Latest Publications
- 19 August 2026
- Published by Springer Nature in Journal of Inclusion Phenomena and Macrocyclic Chemistry
- Vol. 106 (9-10) , 619-638
Conversion of oily β-caryophyllene into a stable and functional powder via β-cyclodextrin inclusion complexation
- 19 August 2026
- Published by Springer Nature in Journal of Inclusion Phenomena and Macrocyclic Chemistry
- Vol. 106 (9-10) , 619-638
Conversion of oily β-caryophyllene into a stable and functional powder via β-cyclodextrin inclusion complexation
- Open Access
- 3 April 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (4) , 785
Development of Self-Administered Formulation to Improve the Bioavailability of Leuprorelin Acetate
In recent years, the development of self-injectable formulations has attracted much attention, and the development of formulations to control pharmacokinetics, as well as drug release and migration in the skin, has become an active research area. In the present study, the development of a lipid-based depot formulation containing leuprorelin acetate (LA) as an easily metabolizable drug in the skin was prepared with a novel non-lamellar liquid-crystal-forming lipid of mono-O-(5,9,13-trimethyl-4-tetradecenyl) glycerol ester (MGE). Small-angle X-ray scattering, cryo-transmission electron microscopy, and nuclear magnetic resonance observations showed that the MGE-containing formulations had a face-centered cubic packed micellar structure. In addition, the bioavailability (BA) of LA after subcutaneous injection was significantly improved with the MGE-containing formulation compared with the administration of LA solution. Notably, higher Cmax and faster Tmax were obtained with the MGE-containing formulation, and the BA increased with increasing MGE content in the formulation, suggesting that LA migration into the systemic circulation and its stability might be enhanced by MGE. These results may support the development of self-administered formulations of peptide drugs as well as nucleic acids, which are easily metabolized in the skin.
- 3 April 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (4) , 785
Open AccessDevelopment of Self-Administered Formulation to Improve the Bioavailability of Leuprorelin Acetate
In recent years, the development of self-injectable formulations has attracted much attention, and the development of formulations to control pharmacokinetics, as well as drug release and migration in the skin, has become an active research area. In the present study, the development of a lipid-based depot formulation containing leuprorelin acetate (LA) as an easily metabolizable drug in the skin was prepared with a novel non-lamellar liquid-crystal-forming lipid of mono-O-(5,9,13-trimethyl-4-tetradecenyl) glycerol ester (MGE). Small-angle X-ray scattering, cryo-transmission electron microscopy, and nuclear magnetic resonance observations showed that the MGE-containing formulations had a face-centered cubic packed micellar structure. In addition, the bioavailability (BA) of LA after subcutaneous injection was significantly improved with the MGE-containing formulation compared with the administration of LA solution. Notably, higher Cmax and faster Tmax were obtained with the MGE-containing formulation, and the BA increased with increasing MGE content in the formulation, suggesting that LA migration into the systemic circulation and its stability might be enhanced by MGE. These results may support the development of self-administered formulations of peptide drugs as well as nucleic acids, which are easily metabolized in the skin.